Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jun 13;19(6):e0298772.
doi: 10.1371/journal.pone.0298772. eCollection 2024.

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

Bahman Amani  1 , Behnam Amani  1
Affiliations
Meta-Analysis

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

Bahman Amani et al. PLoS One. .

Abstract

Objective: The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).

Methods: A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023. The Cochrane risk of bias tools were used to assess the quality of included studies. Comprehensive Meta-Analysis software was used to analyze data.

Results: Twenty-one studies including 10,011 patients were examined. The meta-analysis results showed that azvudine and standard of care/placebo (SOC/PBO) were significantly different concerning mortality rate (risk ratio [RR] = 0.48, 95% confidence interval [CI]: 0.40 to 0.57) and negative polymerase chain reaction (PCR) conversion time (standard mean difference = - 0.75, 95% CI: -1.29 to-0.21). However, the two groups did not show significant differences concerning hospital stay, intensive care unit (ICU) admission, and need for mechanical ventilation (P > 0.05). On the other hand, azvudine and nirmatrelvir-ritonavir were significantly different in mortality rate (RR = 0.73, 95% CI: 0.58 to 0.92), ICU admission (RR = 0.41, 95% CI: 0.21 to 0.78), and need for mechanical ventilation (RR = 0.67, 95% CI: 0.51 to 0.89), but the two treatments were not significantly different in negative PCR conversion time, and hospital stay (P > 0.05). The incidence of adverse events between groups was not significant (P > 0.05). The certainty of evidence was rated as low or moderate.

Conclusions: The antiviral effectiveness of azvudine against SARS-COV-2 is questionable with regard to the certainty of evidence. Further research should be conducted to establish the effectiveness and safety of azvudine in COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow chart of literature screening.
Fig 2
Fig 2. Forest plot of Azvudine vs. standard of care/placebo (SOC/PBO) for mortality rate.
Fig 3
Fig 3. Forest plot of Azvudine vs. nirmatrelvir-ritonavir for mortality rate.
Fig 4
Fig 4. Forest plot of Azvudine vs. standard of care/placebo (SOC/PBO) for negative PCR conversion time.
Fig 5
Fig 5. Forest plot of Azvudine vs. nirmatrelvir-ritonavir for negative PCR conversion time.
Fig 6
Fig 6. Forest plot of Azvudine vs. standard of care/placebo (SOC/PBO) for hospital stay.
Fig 7
Fig 7. Forest plot of Azvudine vs. nirmatrelvir-ritonavir for hospital stay.
Fig 8
Fig 8. Forest plot of Azvudine vs. standard of care/placebo (SOC/PBO) for adverse events.
See this image and copyright information in PMC

References

    1. Zhang S, Yang Z, Chen ZL, Yue SJ, Zhang S, Tang YP. Why does COVID-19 continue to spread despite mass vaccination? Frontiers in public health. 2022;10:938108. doi: 10.3389/fpubh.2022.938108 - DOI - PMC - PubMed
    1. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis. Journal of Medical Virology. 2023;95(2):e28441. doi: 10.1002/jmv.28441 - DOI - PMC - PubMed
    1. Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine. 2023; doi: 10.1016/S2213-2600(22)00528-8 - DOI - PMC - PubMed
    1. Benaicha K, Khenhrani RR, Veer M, et al. Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis. Cureus. 2023;15(5). doi: 10.7759/cureus.38586 - DOI - PMC - PubMed
    1. Cegolon L, Pol R, Simonetti O, Larese Filon F, Luzzati R. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals. 2023;16(5):721. doi: 10.3390/ph16050721 - DOI - PMC - PubMed

Substances